10-Q: Veeva Systems Reports Strong Q3 Growth, Navigates CRM Transition

Veeva Systems Inc. announced robust financial results for the third quarter and first nine months of fiscal year 2026, driven by strong subscription services growth and strategic R&D investments, while managing its CRM platform migration.

Summary

• Total revenues increased 16% to $811.2 million for the three months ended October 31, 2025, and 16% to $2.36 billion for the nine months ended October 31, 2025.
• Subscription services revenues grew 17% to $682.5 million for the quarter and 18% to $1.98 billion for the nine months.
• Net income rose 27% to $236.2 million for the quarter and 28% to $664.7 million for the nine months.
• Diluted EPS increased 24% to $1.40 for the quarter and 26% to $3.96 for the nine months.
• Cash, cash equivalents, and short-term investments totaled $6.6 billion as of October 31, 2025.
• Net cash provided by operating activities increased 28% to $1.31 billion for the nine months, partly due to the One Big Beautiful Bill Act (OBBBA).
• Professional services gross margin decreased to 18% for the quarter (from 22% in prior year) due to headcount expansion.
• General and administrative expenses decreased 5% for the quarter due to a CEO equity grant being fully recognized in the prior year, but increased 20% for the nine months due to litigation settlement-related charges and a CEO equity grant.
• The company is actively migrating customers from its Salesforce-dependent Veeva CRM to its proprietary Vault CRM platform, with Veeva CRM support ending September 1, 2030.

Sentiment

Score: 8

Explanation: Veeva Systems delivered strong financial results with double-digit growth in revenues, net income, and EPS, demonstrating robust operational performance. The company is strategically investing in R&D and managing its CRM platform transition. However, the professional services gross margin decline and the significant risks associated with competitive pressures, regulatory changes, and the CRM migration warrant a balanced view.

Positives

• Strong revenue growth: 16% for both the quarter and nine months ended October 31, 2025.
• Robust subscription services revenue growth: 17% for the quarter and 18% for the nine months, driven by expanding use by existing customers and annual inflation adjustments.
• Significant increase in net income: 27% for the quarter and 28% for the nine months.
• Healthy diluted EPS growth: 24% for the quarter and 26% for the nine months.
• Strong cash position: $6.6 billion in cash, cash equivalents, and short-term investments as of October 31, 2025.
• Increased cash flow from operating activities: 28% increase for the nine months, partly benefiting from the One Big Beautiful Bill Act (OBBBA).
• Growth in R&D Solutions revenue is expected to increase as a percentage of total revenues in the future.
• Successful settlement of all ongoing litigations with IQVIA on August 13, 2025, with neither party paying damages.

Negatives

• Professional services gross margin decreased to 18% for the three months ended October 31, 2025, from 22% in the prior year, primarily due to headcount expansion to support demand.
• Deferred revenue decreased significantly from $1.27 billion at January 31, 2025, to $822.5 million at October 31, 2025, which, while not considered a precise indicator of future revenues by management, could be viewed negatively by analysts.
• Increased effective tax rate for both the three months (24.5% from 23.3%) and nine months (24.2% from 23.1%) ended October 31, 2025, primarily due to the indirect effects of the OBBBA.
• General and administrative expenses increased 20% for the nine months ended October 31, 2025, primarily due to a net increase in litigation settlement-related charges and stock-based compensation related to a CEO equity grant.

Risks

• Security breaches or unauthorized access to customer data could lead to diminished demand, significant liabilities, and reputational damage.
• Highly competitive markets, with competition from Salesforce, IQVIA, Dassault Systèmes, Oracle, Microsoft, and new market entrants, could adversely affect business and operating results.
• Defects or disruptions in solutions could result in diminished demand, reduced revenues, and substantial liability.
• The migration of CRM customers to Vault CRM could cause business disruptions, lead to customer loss to competitors (e.g., Salesforce), and adversely affect operating results.
• Failure of newer solutions (including AI technologies) to be successfully adopted by new and existing customers could adversely affect revenue growth.
• Revenue concentration: top 10 customers accounted for 28% of total revenues in fiscal year ended January 31, 2025, making the company vulnerable to the loss of key customers.
• Near-exclusive dependence on the life sciences industry exposes the company to adverse factors affecting this industry, such as regulatory changes (e.g., drug pricing reforms like the Inflation Reduction Act), industry consolidation, funding environment changes, and geopolitical conditions.
• Uncertain macroeconomic and geopolitical factors (e.g., Russian invasion of Ukraine, Middle East conflict, inflation, interest rates) may cause instability and negatively impact business.
• Difficulty attracting and retaining highly skilled employees could adversely affect business and increase expenses.
• Reliance on third-party providers (Amazon Web Services, Salesforce) for computing infrastructure and network connectivity poses risks of disruption and liability.
• Increasingly complex U.S. and international data privacy and information security regulations (e.g., EU GDPR, UK GDPR, China PIPL, EU Data Act, HIPAA, Washington My Health My Data Act, US DOJ rule on China data) may impose additional compliance costs, reduce demand, and subject the company to liabilities.
• Potential for lawsuits for infringement or misappropriation of third-party intellectual property.
• Acquisitions could divert management attention, result in dilution, and disrupt operations.
• Incorporating AI in solutions or other uses of AI may result in reputational harm and increased liability due to concerns about privacy, security, inefficacy, bias, or evolving regulations (e.g., EU AI Act).
• The EU Data Act, effective September 12, 2025, allows EU customers to cancel subscriptions without cause after a transition period, potentially impacting future revenues.
• China's Personal Information Protection Law (PIPL) has led to certain Veeva CRM customers in China being denied approval to transfer data outside China, potentially leading them to choose other CRM providers.
• The Washington My Health My Data Act has required modifications to audience segments for Veeva Crossix products, which may reduce demand.
• The company's status as a Delaware public benefit corporation (PBC) may not result in anticipated benefits, requires directors to balance stockholder interests with other interests, and may subject the company to legal uncertainty and other risks.
• Evolving expectations and disclosure requirements related to environmental, social, and governance (ESG) matters expose the company to risks that could adversely affect its reputation and performance.
• The common stock price has been and will likely continue to be volatile.

Future Outlook

R&D Solutions revenues are expected to increase as a percentage of both subscription services revenues and total revenues in the future. Cost of subscription services is expected to increase in absolute dollars due to increased usage and continued investment in data solutions. Cost of professional services and other is expected to increase in absolute dollars due to continued investment in the services organization. Operating expenses are expected to increase in the future, primarily due to employee compensation-related costs. Research and development expenses and sales and marketing expenses are also expected to increase. Cash flows from operating activities are expected to increase for the fiscal year ending January 31, 2026, due to the OBBBA. The company believes its existing cash, cash equivalents, and short-term investments will be sufficient to meet working capital and capital expenditure needs over at least the next 12 months. The EU Data Act, effective September 12, 2025, allows EU customers to cancel subscriptions without cause after a transition period, which could impact future revenues.

Management Comments

• Our CEO reviews the financial information presented on a consolidated basis for purposes of allocating resources and evaluating our financial performance.
• We continue to focus our research and development efforts on our platforms, including adding new features and applications and increasing the functionality and enhancing the ease of use of our cloud-based applications.
• We expect operating expenses to increase in the future, primarily due to employee compensation-related costs.
• We believe our existing cash, cash equivalents, and short-term investments will be sufficient to meet our working capital and capital expenditure needs over at least the next 12 months.

Industry Context

Veeva operates as the leading provider of industry cloud solutions for the global life sciences industry, offering software, data, and business consulting from R&D through commercialization. The life sciences industry is subject to complex and evolving global laws and regulations, including data privacy (EU GDPR, UK GDPR, China PIPL, HIPAA, Washington My Health My Data Act) and drug pricing reforms (Inflation Reduction Act), which can impact demand for Veeva's solutions. Industry consolidation and changes in market conditions, such as a preference for digitally-enabled sales channels, can affect demand for solutions like Veeva CRM. The company is navigating the competitive landscape by migrating its CRM customers to its proprietary Vault CRM platform, moving away from its reliance on Salesforce. The rapid development of AI technologies presents both opportunities for new offerings (Veeva AI initiative) and new risks related to privacy, security, and regulatory scrutiny.

Corporate Governance

Legal Proceedings

• On August 13, 2025, Veeva and IQVIA entered into a settlement agreement that resolved all ongoing litigations between them, with neither party paying damages.
• The company may be involved in other legal proceedings and claims incident to the ordinary course of business, but currently believes no outcome would have a material adverse effect.

Stakeholder Impact

• Shareholders: Positive financial performance (revenue, net income, EPS growth) and strong cash position are beneficial. Risks related to stock price volatility, potential dilution from equity awards, and the balancing act of a Public Benefit Corporation (PBC) could impact returns.
• Employees: Continued investment in R&D, sales, marketing, and professional services organizations indicates growth and job opportunities. Stock-based compensation is a significant part of overall compensation. Difficulty attracting and retaining highly skilled employees is a risk.
• Customers: Expanding use of R&D and Commercial Solutions, new features, and enhanced functionality are positive. Risks include potential defects/disruptions in solutions, challenges with the CRM migration, and the impact of evolving data privacy regulations (e.g., EU Data Act allowing cancellations, China PIPL affecting data transfer).
• Partners: Reliance on third-party computing infrastructure providers (AWS, Salesforce) and potential use of third-party subcontractors for professional services. Salesforce's wind-down period for Veeva CRM impacts the partnership.
• Creditors: Strong cash position and positive cash flow from operations indicate good financial health and ability to meet obligations.

Next Steps

• Continue to focus research and development efforts on platforms, adding new features and applications, and enhancing functionality.
• Invest in the services organization to support future demand for professional services.
• Monitor and assess developments and implications surrounding changes in the global tax environment, including Pillar Two.
• Continue to manage the migration of Veeva CRM customers to Vault CRM, with Veeva CRM support ending September 1, 2030.
• Assess the impact of new accounting pronouncements (ASU 2023-09, ASU 2024-03, ASU 2025-06) on disclosures and financial statements.
• Address the challenges and risks associated with incorporating AI into solutions and internal operations.

Key Dates

Recommendation

Veeva Systems demonstrates strong financial performance with double-digit revenue and earnings growth, a robust cash position, and strategic investments in its product portfolio, including AI. The successful settlement of litigation with IQVIA is also a positive. However, the company faces significant headwinds and uncertainties, including the complex and potentially disruptive migration from Veeva CRM to Vault CRM, intense competition, and an increasingly stringent global regulatory environment for data privacy and the life sciences industry. The decline in professional services gross margin and the impact of new accounting and data privacy regulations (EU Data Act, China PIPL, Washington My Health My Data Act) introduce elements of risk and uncertainty regarding future growth and profitability. While the core business remains strong, these factors suggest a 'hold' recommendation, advising investors to monitor the execution of the CRM migration and the impact of regulatory changes before making further investment decisions.

Keywords

Veeva Systems, VEEV, Life Sciences, Cloud Solutions, CRM, Vault CRM, R&D Solutions, Commercial Solutions, SEC Filing, 10-Q, Financial Results, Subscription Services, Software, Healthcare Technology, Data Cloud, Regulatory Compliance, AI, Cybersecurity, Data Privacy, Public Benefit Corporation